Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.1/18229 |
Resumo: | Objective: The main goal of this work was to identify, describe, characterize, and classify the scientifc evidence regarding the use of pharmacogenomic biomarkers in antidepressant treatment. Methods: The work was developed in two phases: i) a search for pharmacogenomic biomarkers in summaries of antidepressant drugs with marketing authorization in Portugal; and ii) a systematic literature review based on the data obtained in the frst phase, with the main objective of fnding international literature that could describe and characterize previously reported biomarkers and identify other relevant biomarkers. Finally, the levels of evidence and recommendation grades were classifed. Results: Among the 26 drugs with marketing authorization in Portugal, only 16 had pharmacogenomic information. The most widely studied pharmacogenomic biomarker was CYP2D6. These results were mostly supported by the systematic literature review, which yielded 103 papers, 63 of which were ultimately included in the review. The sys‑ tematic literature review also revealed the existence of other relevant biomarkers. Most of the included studies show a good level of evidence, which guarantees reliability and good recommendation grades. For the database (built during phase i), the results were informative but resulted in no specifc recommendations. Conclusions: Most pharmacogenomic variants are not studied or acknowledged by genetic tests, and more scien‑ tifc research is needed to confrm their usefulness. Therefore, only a small number of variants are considered when prescribing antidepressant drugs. In addition, genotyping of patients is not common in clinical practice. |
id |
RCAP_88b9c8bfa110b502e37059fe57430559 |
---|---|
oai_identifier_str |
oai:sapientia.ualg.pt:10400.1/18229 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapyAntidepressantsBiomarkersDepressionPharmacogenomicPharmacotherapyObjective: The main goal of this work was to identify, describe, characterize, and classify the scientifc evidence regarding the use of pharmacogenomic biomarkers in antidepressant treatment. Methods: The work was developed in two phases: i) a search for pharmacogenomic biomarkers in summaries of antidepressant drugs with marketing authorization in Portugal; and ii) a systematic literature review based on the data obtained in the frst phase, with the main objective of fnding international literature that could describe and characterize previously reported biomarkers and identify other relevant biomarkers. Finally, the levels of evidence and recommendation grades were classifed. Results: Among the 26 drugs with marketing authorization in Portugal, only 16 had pharmacogenomic information. The most widely studied pharmacogenomic biomarker was CYP2D6. These results were mostly supported by the systematic literature review, which yielded 103 papers, 63 of which were ultimately included in the review. The sys‑ tematic literature review also revealed the existence of other relevant biomarkers. Most of the included studies show a good level of evidence, which guarantees reliability and good recommendation grades. For the database (built during phase i), the results were informative but resulted in no specifc recommendations. Conclusions: Most pharmacogenomic variants are not studied or acknowledged by genetic tests, and more scien‑ tifc research is needed to confrm their usefulness. Therefore, only a small number of variants are considered when prescribing antidepressant drugs. In addition, genotyping of patients is not common in clinical practice.MDPISapientiaCorreia, CatarinaAlcobia, LucianoLopes, Manuel J.Advinha, Ana M.2022-09-08T09:17:52Z2022-08-302022-09-01T03:19:49Z2022-08-30T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/18229engBMC Psychiatry. 2022 Aug 30;22(1):57610.1186/s12888-022-04225-21471-244Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:30:26Zoai:sapientia.ualg.pt:10400.1/18229Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:07:59.060085Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
title |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
spellingShingle |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy Correia, Catarina Antidepressants Biomarkers Depression Pharmacogenomic Pharmacotherapy |
title_short |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
title_full |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
title_fullStr |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
title_full_unstemmed |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
title_sort |
Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy |
author |
Correia, Catarina |
author_facet |
Correia, Catarina Alcobia, Luciano Lopes, Manuel J. Advinha, Ana M. |
author_role |
author |
author2 |
Alcobia, Luciano Lopes, Manuel J. Advinha, Ana M. |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Sapientia |
dc.contributor.author.fl_str_mv |
Correia, Catarina Alcobia, Luciano Lopes, Manuel J. Advinha, Ana M. |
dc.subject.por.fl_str_mv |
Antidepressants Biomarkers Depression Pharmacogenomic Pharmacotherapy |
topic |
Antidepressants Biomarkers Depression Pharmacogenomic Pharmacotherapy |
description |
Objective: The main goal of this work was to identify, describe, characterize, and classify the scientifc evidence regarding the use of pharmacogenomic biomarkers in antidepressant treatment. Methods: The work was developed in two phases: i) a search for pharmacogenomic biomarkers in summaries of antidepressant drugs with marketing authorization in Portugal; and ii) a systematic literature review based on the data obtained in the frst phase, with the main objective of fnding international literature that could describe and characterize previously reported biomarkers and identify other relevant biomarkers. Finally, the levels of evidence and recommendation grades were classifed. Results: Among the 26 drugs with marketing authorization in Portugal, only 16 had pharmacogenomic information. The most widely studied pharmacogenomic biomarker was CYP2D6. These results were mostly supported by the systematic literature review, which yielded 103 papers, 63 of which were ultimately included in the review. The sys‑ tematic literature review also revealed the existence of other relevant biomarkers. Most of the included studies show a good level of evidence, which guarantees reliability and good recommendation grades. For the database (built during phase i), the results were informative but resulted in no specifc recommendations. Conclusions: Most pharmacogenomic variants are not studied or acknowledged by genetic tests, and more scien‑ tifc research is needed to confrm their usefulness. Therefore, only a small number of variants are considered when prescribing antidepressant drugs. In addition, genotyping of patients is not common in clinical practice. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09-08T09:17:52Z 2022-08-30 2022-09-01T03:19:49Z 2022-08-30T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.1/18229 |
url |
http://hdl.handle.net/10400.1/18229 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
BMC Psychiatry. 2022 Aug 30;22(1):576 10.1186/s12888-022-04225-2 1471-244X |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133325607043072 |